UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 9, 2020

 

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38418   35-2528215

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

19805 N. Creek Parkway

Bothell, WA

  98011
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (786) 459-1831

 

 

(Former name or former address, if changed since last report.):

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   COCP   The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)

 

 

 

   

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 9, 2020, the 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”) was held. At the 2020 Annual Meeting, the Company’s stockholders voted on (i) the election of five members of the Company’s Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1), and (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 (Proposal 2), as described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2020.

 

Set forth below are the voting results on each matter submitted to the stockholders at the 2020 Annual Meeting.

 

Proposal 1. The Company’s stockholders voted to elect the following five individuals as directors to hold office until the next annual meeting of stockholders:

 

Nominee   Votes For     Votes Withheld     Broker
Non-Votes
 
Dr. Gary Wilcox     14,611,420       11,316,974       15,214,675  
Dr. Phillip Frost     14,557,109       11,371,285       15,214,675  
Mr. Roger Kornberg     14,571,489       11,356,905       15,214,675  
Mr. Steven Rubin     11,456,705       14,471,689       15,214,675  
Dr. Anthony Japour     25,812,820       115,574       15,214,675  

 

All five nominees were elected as directors.

 

Proposal 2. The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

 

Votes For     Votes Against     Abstentions  
  37,659,301       1,163,991       2,319,777  

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cocrystal Pharma, Inc.
     
Date: June 15, 2020 By: /s/ James Martin
  Name: James Martin
  Title: Chief Financial Officer

 

   

 

Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Cocrystal Pharma Charts.
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Cocrystal Pharma Charts.